Myriad, ACLU Argue Over Prometheus In Gene Patent Battle

Law360, New York (June 18, 2012, 9:08 PM EDT) -- Myriad Genetics Inc. and the American Civil Liberties Union squared off Friday over the impact of the U.S. Supreme Court's Prometheus ruling on Myriad's gene patents, with the ACLU arguing the decision renders the patents invalid and Myriad saying Prometheus has no bearing on the case.

After handing down Prometheus, which reaffirmed that laws of nature are not patentable, the high court ordered the Federal Circuit to review its finding that Myriad's patents on isolated breast cancer genes are valid because they are "markedly different" for...
To view the full article, register now.